Deutsche Bank raised the firm’s price target on AbbVie (ABBV) to $180 from $175 and keeps a Hold rating on the shares. The company reported a quality Q3, but Emraclidine success looks already priced in, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: